928006-47-7

Basic information

• Product Name: {3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetic acid
• Synonyms: {3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetic acid
• CAS NO: 928006-47-7
• Molecular Weight: 510.679
• Mol File: 928006-47-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: {3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: {3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetic acid(928006-47-7)
• EPA Substance Registry System: {3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetic acid(928006-47-7)

Safety Data

• Hazardous Substances Data: 928006-47-7(Hazardous Substances Data)

Upstream product

• 612-41-9 2-nitrocinnamic acid 
• 88939-75-7 methyl β-(o-aminophenyl)acrylate 
• 39228-29-0 methyl 2-nitrocinnamate 
• 839672-50-3 methyl 3-[2-((4-biphenyl)iminomethyleneamino)phenyl]acrylate 
• 954-81-4 N-(5-bromopentyl)phthalimide 
• 111-24-0 1,5-dibromo-pentane 
• 928006-41-1 2-(5-(pyrrolidin-1-yl)pentyl)isoindoline-1,3-dione 
• 928006-42-2 t-butyl (5-pyrrolidin-1-ylpentyl)carbamate 
• 928006-43-3 N-methyl-5-(pyrrolidin-1-yl)pentan-1-amine 
• 71302-71-1 5-(pyrrolidin-1-yl)pentan-1-amine 
• 928006-45-5 KYS₀₅₀₇₉ 

Relevant articles and documents

3,4-DIHYDROQUINAZOLINE DERIVATIVES

The present invention relates to 3,4-dihydroquinazoline derivatives, a process of preparing them and a pharmaceutical composition including them. The 3,4-dihydroquinazoline derivatives of the present invention have excellent T-type calcium channel blocking effect and anti-cancer activity.

T-type Ca2+ channel blockers suppress the growth of human cancer cells

In order to further clarify the role of T-type Ca2+ channels in cell proliferation, we have measured the growth inhibition of human cancer cells by using our potent T-type Ca2+ channel blockers. As a result, KYS05090, a most potent T-type Ca2+ channel blocker, was found to be as potent as doxorubicin against some human cancer cells without acute toxicity. Therefore, this letter provides the biological results that T-type calcium channel is important in regulating the important cellular phenotype transition leading to cell proliferation, and thus novel T-type Ca2+ channel blocker presents new prospects for cancer treatment.